Effect Of Tamoxifen-Gambogic Acid Combinations on Antiproliferative Activity in Estrogen Receptor-Positive Breast Cancer Cells

8th Drug Chemistry Conference, Antalya, Türkiye, 27 Şubat - 01 Mart 2020, ss.265

Yayın Türü: Bildiri / Özet Bildiri
Basıldığı Şehir: Antalya
Basıldığı Ülke: Türkiye
Sayfa Sayıları: ss.265
Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

Breast cancer is the most frequent cancer among women, affecting approximately 2 million women each year, and also causes the greatest number of cancer-related deaths among women. MCF-7 cell line was derived in 1970 from an effusion of 69-year-old female patient with invasive breast ductal carcinoma1 . Tamoxifen is the most commonly used treatment for patients with oestrogen-receptor positive breast cancer and the WHO lists as an essential drug for the treatment. Due to tamoxifen, approximately more than 500,000 women have gained health today and millions more have benefited from extended disease-free survival2 . Combination therapy created by using two or more therapeutic molecules together is a method that has many advantages over mono-therapy in cancer treatment. The most important of these advantages; lower dose effectiveness, multiple strategies can be used and side effects are reduced3 . Gambogic acid is an anticancer traditional medicine that is isolated from Garcinia hanburyi. Gambogic acid that have been reported for its cytotoxic/anti-proliferative effects, has shown the ability to regulating multiple signaling pathways ranging from PI3K/AKT, mTOR to inhibition of histone acetylase transferase4,5 . Aim of the present study is to investigate antiproliferative effect of combination of Tamoxifen - Gambogic acid on MCF-7 human breast cancer cells by XTT method and values were calculated by CompuSyn software. In addition, the expression levels of some genes (Bcl2, Caspase-3, caspase-9 and Bax) were analyzed at both mRNA and protein levels using RT-qPCR and ELISA methods.